The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ATYR | -79.29% | -78.62% | -26.55% | -100% |
| S&P | +14.49% | +91.09% | +13.83% | +224% |
aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
The next couple of weeks could reveal a great deal about this stock's prospects.
Clinical trial results expected in the weeks ahead could push shares of these small-cap drugmakers through the roof.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.19M | 0.0% |
| Gross Profit | -$0.20M | 48.7% |
| Gross Margin | -104.74% | 0.0% |
| Market Cap | $70.69M | -47.0% |
| Market Cap / Employee | $1.20M | 0.0% |
| Employees | 59 | 0.0% |
| Net Income | -$25.75M | -49.2% |
| EBITDA | -$26.36M | -48.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $6.15M | -46.3% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $10.93M | -11.6% |
| Short Term Debt | $1.43M | 18.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -75.78% | -16.9% |
| Return On Invested Capital | -52.28% | 4.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$20.51M | -55.7% |
| Operating Free Cash Flow | -$20.48M | -55.6% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 4.20 | 3.62 | 6.01 | 0.90 | -56.18% |
| Price to Sales | 191.77 | 567.71 | 1274.31 | 368.88 | 68.33% |
| Price to Tangible Book Value | 4.20 | 3.62 | 6.01 | 0.90 | -56.18% |
| Enterprise Value to EBITDA | -15.37 | -12.84 | -19.52 | 0.30 | -106.63% |
| Return on Equity | -79.7% | -79.5% | -85.2% | -103.2% | 32.40% |
| Total Debt | $13.28M | $12.99M | $12.68M | $12.36M | -8.92% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
